Inflammatory Markers and Cognitive Function in Major Depression
NCT ID: NCT01391221
Last Updated: 2012-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
20 participants
INTERVENTIONAL
2011-07-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Duloxetine treatment
Subjects with major depression will be entered into the trial and treated with open label duloxetine
Duloxetine
Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Duloxetine
Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Unstable or untreated medical disorders
* Medical disorders associated with pain
* Recent pregnancy or delivery
* Psychiatric disorders other than MD which are the primary focus of treatment
* Treatment with antidepressants in the past 4 weeks
20 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Smadar Valerie Tourjman
MDCM, FRCPc, MSc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de Recherche Fernand Seguin
Montreal, Quebec, Canada
Hôpital Maisonneuve Rosemont
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Louise Normandeau, nursing
Role: primary
Souad Lhalafi, nursing
Role: backup
Marie Eve Koue, MSc
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011005
Identifier Type: -
Identifier Source: org_study_id